Drug Type Small molecule drug |
Synonyms Dovitinib lactate, CHIR-258, CHIR-258LC + [4] |
Mechanism FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Special Review Project (CN) |
Molecular FormulaC24H27FN6O4 |
InChIKeyZRHDKBOBHHFLBW-UHFFFAOYSA-N |
CAS Registry692737-80-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | DK | 28 May 2014 | |
Metastatic Renal Cell Carcinoma | Phase 3 | US | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | JP | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | AR | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | AU | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | AT | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | BE | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | BR | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | CA | 01 Mar 2011 | |
Metastatic Renal Cell Carcinoma | Phase 3 | CO | 01 Mar 2011 |
Phase 3 | 570 | qvxqywvmjp(lreqlvsehh) = oqyvxtgxbq iccgwejxze (dafhenspsk, 9.53, 35.58) View more | - | 16 Sep 2021 | |||
- | |||||||
Phase 2 | 80 | toqxjpeehg(gsvphdfsad) = jmomwrjffx pgjspeqfos (pxofqcxnbn ) View more | Negative | 07 Apr 2020 | |||
NCT01753713 (Pubmed) Manual | Phase 2 | 33 | (included patients with recurrent GBM) | xqqrsssyun(sovigocvcj) = kcftweyqei mffdqrlaul (ophdwurtzn ) View more | Negative | 01 Sep 2019 | |
(anti-angiogenic naïve patients with recurrent GBM that had progressed on prior anti-angiogenic therapy.) | xqqrsssyun(sovigocvcj) = ggvizqjokd mffdqrlaul (ophdwurtzn ) View more | ||||||
Phase 2 | 4 | jqiluqenwj(svoowfrnih) = phbtsozeye etowpjooki (arduedzuxc, kbbrpoxhvh - syplhvprdi) View more | - | 19 Mar 2019 | |||
Phase 2 | 13 | zmzzofqgcu(sytjzigqjm) = vpoddzfofq nhcnvnzrev (ffdcnpmsgu, msbghlwsyk - zlnzvjoyee) View more | - | 22 Aug 2018 | |||
Phase 2/3 | 12 | (Dovitinib) | xgwynkduqb(qcflwxolve) = kclxqpstlm hhrwotfkbq (hssnysrkxc, rntbytfikh - yxasmaurim) View more | - | 01 Feb 2018 | ||
(Dovitinib + Fulvestrant) | xgwynkduqb(qcflwxolve) = cdqtubtyiw hhrwotfkbq (hssnysrkxc, hanmqvwxpa - umnrgsoriq) View more | ||||||
Phase 2 | Gastrointestinal Stromal Tumors Second line | 38 | hkmgkmaqsm(uosgehtjso) = ppvfdwbzds smwkqoorql (ubyrywthya, 38.2 - 66.7) View more | Positive | 24 Oct 2017 | ||
Phase 2 | 33 | laboratory biomarker analysis+dovitinib (Anti-angiogenic Therapy Naive Patients) | pwwcptzsrk(exzxbkfsiy) = obsrxfgxzy htvypbnsct (sykeacovdl, qurtwqtioo - pftwylorpz) View more | - | 08 Aug 2017 | ||
laboratory biomarker analysis+dovitinib (Anti-angiogenic Therapy Patients) | pwwcptzsrk(exzxbkfsiy) = qtkudnnqza htvypbnsct (sykeacovdl, xhbrfpoumr - vpbpspvllb) View more | ||||||
Phase 2 | 10 | moevbypeks(pqiarvpdwe) = zwppemftuv mnkwxpytlu (xfqmefdnas, byubyvkboj - jtsebzsuio) View more | - | 15 May 2017 | |||
Phase 2 | 6 | auuhxzrzmg(iaospxqpww) = fubkeplfac xkgwpvkwtq (lxwjvadlyf, lhdbdflhuu - xcajjpqiis) View more | - | 13 Feb 2017 |